Onconetix Inc（ONCO）の株式分析ONCOOnconetix Inc

Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Onconetix Inc is not a good buy right now due to its current price of $0.42, which is down 99.48% year-to-date, and an RSI of 26.369 indicating it is oversold. The company has reported a gross margin of only 25.13% in Q2 2026, which is significantly lower than previous quarters, and a negative net income of -$2,867,303 in the same quarter. The main risk is the substantial 5-day change of -12.70%, reflecting ongoing volatility and lack of investor confidence.